La cadena de opciones muestra datos clave de las opciones de acciones de Tango Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Tango Therapeutics..

Tango Therapeutics (NASDAQ:TNGX) Bolsa, Cadena de Opciones

Tango Therapeutics

Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.

Tango Therapeutics Inc

Piper Sandler analyst Brent Bracelin upgrades ZoomInfo Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZI#NASDAQ">ZI</a>) from Underweight to Neutral and raises the price target from $10 to $11.

News

Upgrades

Price Target

Analyst Ratings

Piper Sandler Upgrades ZoomInfo Technologies to Neutral, Raises Price Target to $11

Billionaire Ray Dalio cautioned investors in a recent podcast interview with Tucker Carlson saying that the development of artificial intelligence could risk totalitarian social control or even anarchy in the coming years.
Highlighting the unpredictability in the direction of AI's growth, Dalio anticipated a radically different world over the next five years.
What Happened: Dalio recently appeared on a podcast with Carlson on the latter's YouTube channel discussing the trends in the U.S. economy, debt crisis, stock market, and AI.
Discussing the various possibilities of using AI at a "molecular level," from solving medical issues to problems like inflation within an economy, Dalio said that AI was a "two-edged sword". The future could be shaped depending on who has access to and control of such AI tools, he said.
When asked if there was a way to avoid totalitarian social control through AI, Dalio said, "I think there&#8217;s a question of whether you can have social and totalitarian controls or maybe you just have anarchy."
Dalio believes that humanity will undergo an AI technology-induced "time warp," which will radically change the world in the next five years. He also added that quantum computing will be another innovation to look at.
"So the world five years from now is going to be a radically different world. And I don&#8217;t know what that&#8217;s going to look like when you go into the world of quantum computing and what quantum is like in so many different ways. It raises questions of, you know, what is that like?" said Dalio.
See Also: <a href="https://www.benzinga.com/25/02/43932776/mark-cuban-slams-fd-up-healthcare-system-blames-insurance-designed-deductibles-for-patient-bankruptcy">Mark Cuban Calls Deductibles &#8216;The Biggest Problem&#8217; in Healthcare: &#8216;System…Needs To Be Redesigned&#8217;</a>
Why It Matters: Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) launched ‘Majorana 1,' last week which is one of its kind quantum computing chip operating in a topological phase of matter. While Satya Nadella termed it a "physics breakthrough," he added that the launch of this chip could shorten the timeline of a possible quantum computing breakthrough.
Similarly, with DeepSeek's emergence, the competition in the AI industry has also intensified. Here is a list of AI and quantum computing-linked exchange-traded funds that investors could consider over the long term.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>ETF Name</td>
<td>YTD Performnace</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>iShares US Technology ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYW#NYSE">IYW</a>)</td>
<td>7.55%</td>
<td>0.90%</td>
</tr>
<tr>
<td>Fidelity MSCI Information Technology Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTEC#NYSE">FTEC</a>)</td>
<td>-2.57%</td>
<td>17.89%</td>
</tr>
<tr>
<td>First Trust Dow Jones Internet Index Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDN#NYSE">FDN</a>)</td>
<td>0.80%</td>
<td>22.78%</td>
</tr>
<tr>
<td>iShares Expanded Tech Sector ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGM#NYSE">IGM</a>)</td>
<td>-1.14%</td>
<td>20.91%</td>
</tr>
<tr>
<td>iShares Global Tech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IXN#NYSE">IXN</a>)</td>
<td>-0.66%</td>
<td>14.81%</td>
</tr>
<tr>
<td>Defiance Quantum ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTUM#NASDAQ">QTUM</a>)</td>
<td>-1.93%</td>
<td>37.08%</td>
</tr>
</tbody>
</table>
</figure>
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, rose in premarket on Wednesday. SPY was up 0.45% to $596.94, and QQQ advanced 0.75% to $517.16, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43936887/amazon-exceeds-walmart-q4-revenue-which-was-77x-lower-in-2000-took-25-years-contrary-to-jeff-bezos-10-year-overnight-success-statement-in-2018">Jeff Bezos Once Said &#8216;Overnight Success&#8217; Takes 10 Years. It Took Amazon 25 Years To Surpass Walmart&#8217;s Revenue</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

Government

Financing

Events

Markets

Tech

First Trust Dow Jones Internet Index Fund

FTEC

iShares Trust S&P Global Information Technology Sector Index Fund

iShares Dow Jones US Technology Sector Index Fund

MSFT

QTUM

Billionaire Ray Dalio Says AI Risks 'Totalitarian Control Or Anarchy' As It Could Reshape World In Next 5 Years: Here Are AI-Linked ETFs For Investors To Consider

HC Wainwright &amp; Co. analyst Oren Livnat reiterates Tarsus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARS#NASDAQ">TARS</a>) with a Buy and maintains $73 price target.

Reiteration

TARS

HC Wainwright & Co. Reiterates Buy on Tarsus Pharmaceuticals, Maintains $73 Price Target

WIIM

Mablebear shares are trading lower after the company reported worse-than-expected Q4 revenue results.

NGVC

Natural Grocers Says It Expanded Private-Label Beverage Line With 100% Pure Organic Coconut Water

Anheuser-Busch InBev shares are trading higher after the company reported better-than-expected Q4 earnings and revenues.

Piper Sandler analyst Brent Bracelin maintains Workday (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) with a Neutral and raises the price target from $270 to $290.

WDAY

Piper Sandler Maintains Neutral on Workday, Raises Price Target to $290

HC Wainwright &amp; Co. analyst Andres Maldonado maintains Day One Biopharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAWN#NASDAQ">DAWN</a>) with a Buy and lowers the price target from $40 to $36.

DAWN

HC Wainwright & Co. Maintains Buy on Day One Biopharmaceutical, Lowers Price Target to $36

Piper Sandler analyst Arvind Ramnani reiterates CCC Intelligent Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCCS#NASDAQ">CCCS</a>) with a Neutral and lowers the price target from $13 to $11.

CCCS

Piper Sandler Reiterates Neutral on CCC Intelligent Solutions, Lowers Price Target to $11

First Quarter Fiscal 2026 Outlook
For the quarter ending April 26, 2025, the Company currently expects the following:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Contract revenues</td>
<td>$1.16 billion to $1.20 billion</td>
</tr>
<tr>
<td>Non-GAAP Adjusted EBITDA</td>
<td>$130.6 million to $140.6 million</td>
</tr>
<tr>
<td>Diluted Earnings per Common Share</td>
<td>$1.50 to $1.73</td>
</tr>
</tbody>
</table>
</figure>
&nbsp;

Guidance

Dycom Industries Q1 Adj. EPS Outlook $1.50-$1.73 Vs, $1.81 Estimate

BLMN

Bloomin' Brands Sees FY25 Adj. EPS $1.20-$1.40 Vs $1.77 Estimate

Needham analyst Joseph Stringer reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and maintains $320 price target.

ALNY

Needham Reiterates Buy on Alnylam Pharmaceuticals, Maintains $320 Price Target

Buybacks

VRSK

On Feb 19, Verisk Board Approved An Additional Share Repurchase Authorization Of Up To $1.0B

This preliminary assessment reveals possible recovery of an additional 20 million barrels of oil and 16 billion cubic feet of natural gas in the lower intervals of the San Andres. The Company's current, on-going waterflood program has proven reserves of 15 million barrels of oil and 3 billion cubic feet of natural gas.
This preliminary assessment is the first step in an ongoing, comprehensive, multi-disciplinary analysis of the field incorporating petrophysics, geology and engineering data. The preliminary assessment uses modern geoscience software and workflows, which will ultimately lead to a 3D geologic model incorporating extensive well control. The ongoing multi-disciplinary work indicates the presence of previously unrecognized intervals and is expected to identify new drilling locations.
The preliminary assessment indicates that the significant volumes of stranded oil present in the lower San Andres beneath the Company's approximately 13,700-acre position is best exploited by drilling 5,000 foot horizontal wells.

EONR

EON Resources Completes Preliminary Assessment, Identifying 20 Million Untapped Barrels In San Andres Formation

Piper Sandler analyst Brent Bracelin maintains Couchbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>) with a Overweight and raises the price target from $21 to $22.

BASE

Piper Sandler Maintains Overweight on Couchbase, Raises Price Target to $22

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Bicycle Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCYC#NASDAQ">BCYC</a>) with a Buy and maintains $33 price target.

BCYC

HC Wainwright & Co. Reiterates Buy on Bicycle Therapeutics, Maintains $33 Price Target

Covestro (OTC:<a class="ticker" href="https://www.benzinga.com/stock/COVTY#OTC">COVTY</a>) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.74) by 27.03 percent. This is a 440 percent decrease over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $3.60 billion which beat the analyst consensus estimate of $3.49 billion by 3.31 percent. This is a 5.48 percent decrease over sales of $3.81 billion the same period last year.

Earnings

Earnings Beats

COVTY

Covestro Q4 EPS $(0.54) Beats $(0.74) Estimate, Sales $3.60B Beat $3.49B Estimate

KBLB

Kraig Biocraft Laboratories Doubles Complexity And Size Of Spider Silk Gene Insert, Advancing Material Performance

SMCI: 28% &#x7C; <a href="https://www.benzinga.com//node/43967143">SMCI Stock Pops Over 26% In Wednesday Pre-Market After Super Micro Computer Says It 'Regained Compliance'</a>
&nbsp;
ENVB: 193% &#x7C; <a href="https://www.benzinga.com//node/43956672">EXCLUSIVE: Non-Hallucinogenic Psychedelic Compounds Show Promise For Treating Addiction And ADHD</a>
&nbsp;
AXON: 16% &#x7C; <a href="https://www.benzinga.com//node/43968079">Axon Enterprises shares are trading higher after the company reported better-than-expected Q4 financial results and issued FY24 revenue guidance with its midpoint above estimates.</a>

Movers

Trading Ideas

AXON

ENVB

SMCI

Market-Moving News for February 26th

Transaction Details
Pursuant to the terms and conditions of the Arrangement Agreement, the holders of the issued and outstanding QPM Shares will receive 0.0741 Fury Shares for each one (1) QPM Share held (the "Exchange Ratio"). QPM stock options and warrants that are outstanding at the time of completion of the Transaction will become exercisable for Fury Shares on substantially the same terms and conditions, with the number of Fury Shares issuable on exercise and the exercise price adjusted in accordance with the Exchange Ratio. The Transaction will be carried out by way of a court-approved plan of arrangement under the Canada Business Corporations Act.
The Exchange Ratio implies a price of C$0.04 per QPM Share and a premium of approximately 33% based on the closing prices of Fury and QPM on February 25, 2025 and a premium of approximately 28% based on the 20-day volume weighted average prices of Fury Shares and QPM Shares as of February 25, 2025. Upon completion of the Transaction, existing Fury and QPM shareholders would own approximately 95% and 5% of the combined company, respectfully, on an undiluted basis.
Upon completion of the Transaction, Fury will continue to be listed on the TSX and NYSE American under the same Fury name and ticker symbol. The Arrangement Agreement contains customary deal-protection provisions including a non-solicitation covenant on the part of QPM and a right for Fury to match any Superior Proposal (as defined in the Arrangement Agreement). Under certain circumstances, either Fury or QPM would be entitled to a termination fee of C$0.2 million.

FURY

Fury Gold Mines To Acquire Quebec Precious Metals In Stock Deal, Expanding Quebec Exploration Portfolio

Press Releases

Medivir's licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program

Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Tango Therapeutics to Participate in Upcoming Investor Conferences

Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program

Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference

Tango Therapeutics to Present at Three Upcoming Investment Bank Conferences

TNGX

Abeona Therapeutics

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Comments

Tango Therapeutics

Tango Therapeutics (TNGX) Opciones

Tango Therapeutics (NASDAQ:TNGX) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL